Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 1:42 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 95 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: norgestrel Clear all

Conditions: Pregnancy Prevention
Interventions: Levonorgestrel 1.5mg, Meloxicam 15 mg, Placebo; Drug · Other
Lead sponsor: InnovaGyn, Inc.; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Raleigh, North Carolina

Conditions: Pregnancy
Interventions: levonorgestrel 0.75mg taken twice 12 hours apart (Plan B) and condoms; Drug
Lead sponsor: University of Washington; Other
Eligibility: 16 Years to 60 Years · Female only
Enrollment: 177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Contraception, Malposition of Intrauterine Contraceptive Device
Interventions: Levonorgestrel Intrauterine System (LNG-IUS); Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: HIV Infections, Contraception, Pharmacokinetics
Interventions: levonorgestrel, efavirenz; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 2
States / cities: Denver, Colorado • Providence, Rhode Island

Conditions: Pregnancy
Interventions: Mirena (Levonorgestrel IUS, BAY86-5028), ParaGard, Implanon/Nexplanon; Drug
Lead sponsor: Bayer; Industry
Eligibility: 15 Years to 44 Years · Female only
Enrollment: 13,880 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Healthy Volunteer
Interventions: ABBV-295, Levonorgestrel/Ethinyl Estradiol; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 2
States / cities: Anaheim, California • Grayslake, Illinois

Conditions: Heavy Menstrual Bleeding, Bleeding Disorder, Von Willebrand Diseases
Interventions: Levonorgestrel Intrauterine System, Norethindrone Acetate; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 10 Years to 24 Years · Female only
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 8
States / cities: Palo Alto, California • Aurora, Colorado • Atlanta, Georgia + 5 more

Conditions: Initiation of Oral Contraception (OC), Initiation of Depo-Provera (DMPA), Initiation of Mirena (LNG-IUD)
Interventions: Mirena, Oral contraception, Depo-Provera; Drug
Lead sponsor: Thomas Cherpes, DVM, MD; Other
Eligibility: 15 Years to 25 Years · Female only
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Healthy Participants
Interventions: AZD6234, Ethinyl estradiol/Levonorgestrel (EE/LEVO), Acetaminophen (APAP), AZD9550; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 35 Years to 75 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Glendale, California • Brooklyn, Maryland

Conditions: Emergency Contraception
Interventions: CDB-2914, levonorgestrel; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older · Female only
Enrollment: 1,672 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1999 – 2001
U.S. locations: 6
States / cities: Los Angeles, California • Denver, Colorado • New York, New York + 3 more

Conditions: HIV Prevention
Interventions: Tenofovir 1% vaginal gel, Depo-medroxyprogesterone acetate (DMPA), Oral contraceptive: LNG 150 mcg and EE 30 mcg; Drug
Lead sponsor: CONRAD; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 2
States / cities: Pittsburgh, Pennsylvania • Norfolk, Virginia

Conditions: Anorexia Nervosa, Osteoporosis
Interventions: estradiol 0.045 mg/levonorgestrel 0.015mg; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 25 Years to 50 Years · Female only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Pregnancy
Interventions: Copper T380 IUD, levonorgestrel; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 57 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: West Valley City, Utah

Conditions: Premenstrual Syndrome
Interventions: Levonorgestrel/Ethinyl Estradiol; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 48
States / cities: Huntsville, Alabama • Peoria, Arizona • Phoenix, Arizona + 40 more

Conditions: Contraception
Interventions: Gestodene/EE (FC Patch Low, BAY86-5016), Oral contraceptive (equivalent to the active treatment tablets of Levlite), 21-day blister SH D00593A; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 346 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 28
States / cities: Chandler, Arizona • Glendale, Arizona • Phoenix, Arizona + 25 more

Conditions: Healthy Participants
Interventions: Elenestinib, Midazolam, Levonorgestrel/Ethinyl Estradiol; Drug
Lead sponsor: Blueprint Medicines Corporation; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Contraception
Interventions: Norgestrel 0.075 mg tablets; Drug
Lead sponsor: HRA Pharma; Industry
Eligibility: 12 Years and older · Female only
Enrollment: 189 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 44
States / cities: Birmingham, Alabama • Homewood, Alabama • McCalla, Alabama + 38 more

Conditions: Healthy Volunteers
Interventions: CTP-543, Combined oral contraceptive containing Ethinyl estradiol (EE) and Levonorgestrel (LNG); Drug
Lead sponsor: Concert Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Body Weight, Contraceptive Usage
Interventions: All participants (Aviane), Portia, Aviane; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Emergency Contraception
Interventions: DR-104; Drug
Lead sponsor: Duramed Research; Industry
Eligibility: 11 Years to 16 Years · Female only
Enrollment: 343 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 5
States / cities: San Francisco, California • Atlanta, Georgia • Minneapolis, Minnesota + 2 more

Conditions: Contraception
Interventions: Ulipristal Acetate, Combined Oral Contraceptive Pill; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 39 Years · Female only
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 2
States / cities: New York, New York

Conditions: Abnormal Uterine Bleeding, Unspecified, Uterine Bleeding Heavy
Interventions: EE 30mcg/LNG 150mcg, Placebo; Drug
Lead sponsor: University of California, Davis; Other
Eligibility: 14 Years and older · Female only
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 2
States / cities: Sacramento, California • St Louis, Missouri

Conditions: Hormonal Contraception
Interventions: Depot medroxyprogesterone acetate (DMPA), Etonogestrel implant (Eng-Implant), Levonorgestrel IUD (Lng-IUD); Drug
Lead sponsor: Emory University; Other
Eligibility: Up to 45 Years · Female only
Enrollment: 155 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 3
States / cities: Atlanta, Georgia

Conditions: Contraceptive Usage
Interventions: Levonorgestrel IUD; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older · Female only
Enrollment: 93 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Search by objective public record fields.

Oral Levonorgestrel Plus Meloxicam, IG-002 Delays Ovulation in Normal Menstruating Women by Seven Days

Randomized Trial of Advanced Provision Emergency Contraception Among Women With Gonorrhea or Chlamydia

LNG-IUS at 2 Weeks Postpartum

A Study of the Drug Interactions Between a Hormonal Emergency Contraception and an HIV Medication

Duration of Use of Highly Effective Reversible Contraception

A Study of ABBV-295 Subcutaneous Injections to Assess Pharmacokinetics and Adverse Events in Healthy Adult Women Participants With Overweight or Obesity Taking Oral Contraceptives

Heavy Menstrual Bleeding Progestin Treatment in Bleeding Disorders Study

Modulation of Mucosal and Systemic Immunity by Hormonal Contraceptives

A Study to Investigate the Effect of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or Obesity

Efficacy Trial of CDB 2914 for Emergency Contraception

Contraception and Menstrual Cycle Effect on Pharmacokinetics, Pharmacodynamics and Safety in Tenofovir Vaginal Gel Use

Transdermal Estrogen in Older Premenopausal Women With Anorexia Nervosa

Copper T380 IUD Versus Oral Levonorgestrel for Emergency Contraception vs. Plan B for Emergency Contraception

Study Evaluating Levonorgestrel/Ethinyl Estradiol (LNG/EE) in PMS

US Cycle Control and Blood Pressure Study

A Study of Elenestinib in Healthy Adult Female Participants

A Study of Oral Contraception Under Simulated OTC Conditions

Drug-drug Interaction Study of CTP-543 and Oral Contraceptives in Healthy Female Subjects

Oral Contraceptives and Body Mass Index

Emergency Contraception Actual Use Study

Compare Daily Ulipristal Acetate and Combined Oral Contraceptive Effects on Breast Epithelial Cell Proliferation

Treatment of Unacceptable Bleeding Patterns in ETG Implant Users With an Oral Contraceptive

Contraceptive Hormones, Immunity, and Microbiome Evaluation

'Levonorgestrel IUD Insertion After D&E Procedure